Assessing TP53 status in human tumours to evaluate clinical outcome

Nature Reviews Cancer

Volumn 1, Issue 3, 2001, Pages 233-240

  Soussi, Thierry ^a   Béroud, Christophe ^b  

^a INSTITUT CURIE   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CKAP4 PROTEIN, HUMAN; DNA BINDING PROTEIN; MEMBRANE PROTEIN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; PROTEIN P53; TP73L PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

AMINO ACID SUBSTITUTION; CHEMISTRY; FAMILIAL CANCER; GENE DELETION; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOSITY LOSS; HUMAN; MISSENSE MUTATION; MORTALITY; MUTATION; NEOPLASM; PHYSIOLOGY; POINT MUTATION; PROGNOSIS; REVIEW; RNA SPLICING; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

AMINO ACID SUBSTITUTION; DNA-BINDING PROTEINS; GENE DELETION; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; LI-FRAUMENI SYNDROME; LOSS OF HETEROZYGOSITY; MEMBRANE PROTEINS; MUTATION; MUTATION, MISSENSE; NEOPLASMS; NUCLEAR PROTEINS; PHOSPHOPROTEINS; POINT MUTATION; POLYMORPHISM, GENETIC; PROGNOSIS; RNA SPLICE SITES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0035751937     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/35106009     Document Type: Article

References (24)

1. Vousden, K. H. p53. Death star. Cell 103, 691-694 (2000).
2. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
3. Soussi, T., Dehouche, K. & Béroud, C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum. Mutat. 15, 105-113 (2000).
4. Moll, U. M., Laquaglia, M., Benard, J. & Riou, G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl Acad Sci. USA 92, 4407-4411 (1995).
5. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., Georges, D. L. & Vogelstein, B. Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature 358, 80-83 (1992).
6. Crook, T. et al. Clonal p53 mutation in primary cervical cancer- association with human-papillomavirus-negative tumours. Lancet 339, 1070-1073 (1992).
7. Soengas, M. S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207-211 (2001).
8. Bell, D. W. et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286, 2528-2531 (1999).
9. Rotman, G. & Shiloh, Y. ATM: a mediator of multiple responses to genotoxic stress. Oncogene 18, 6135-6144 (1999).
10. Baker, S. J. et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244, 217-221 (1989).
11. Takahashi, T. et al. p53- a frequent target for genetic abnormalities in lung cancer. Science 246, 491-494 (1989).
12. Nigro, J. M. et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342, 705-708 (1989).
13. Dowell, S. P., Wilson, P. O. G., Derias, N. W., Lane, D. P. & Hall, P. A. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res. 54, 2914-2918 (1994).
14. Varley, J. M. et al. Characterization of germline TP53 splicing mutations and their genetic and functional analysis. Oncogene 20, 2647-2654 (1999).
15. Gu, J., Kawai, H., Wiederschain, D. & Yuan, Z. M. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain. Cancer Res. 61, 1741-1746 (2001).
16. Hashimoto, T. et al. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res. 59, 5572-5577 (1999).
17. Skaug, V. et al. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin. Cancer Res. 6, 1031-1037 (2000).
18. Tomizawa, Y. et al. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 18, 1007-1014 (1999).
19. Schiller, J. H. et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J. Clin. Oncol. 19, 448-457 (2001).
20. Hartmann, A., Blaszyk, H., Kovach, J. S. & Sommer, S. S. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet. 13, 27-33 (1997).
21. Kern, S. E. et al. Mutant p53 proteins bind DNA abnormally in vitro. Oncogens 6, 131-136 (1991).
22. El-Deiry, W. S., Kern, S. E., Pientenpol, J. A., Kinzler, K. W. & Vogelstein, B. Definition of a consensus binding site for p53. Nature Genet. 1, 45-49 (1992).
23. Kern, S. E. et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830 (1992).
24. Milner, J. & Medcalf, E. A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65, 765-774 (1991).